Dr. Patrik Frei was the keynote speaker at BIO IP & Diagnostics Symposium (IPDx) on 29th of September 2017. During the session, the Venture Valuation CEO discussed the valuation of biotechnology companies and products and its link to IP. He gave a short introduction to risk-adjusted net present value calculations, the main value drivers and … Continue reading BIO IP & Diagnostics Symposium (IPDx) Keynote Session
During the last RESI (Redefining Early Stage Investments) Conference – the event series organized by Life Science Nation, a Venture Valuation long-time partner – Dr. Patrik Fried delivered a session on life science deal and product valuations. The notes from the workshop are available to download here
Inventiveness in peptide drug technology and a well thought- out business strategy characterize PeptiDream’s thriving growth. Venture Valuation (VV) interviewed Kiichi Kubota, co-founder and Chairman. Read the interview
Venture Valuation CEO, Dr. Patrik Frei is one of the experts working as mentors for MassChallengeCH, a famous startup accelerator. He helps new entrepreneurs understand the concepts and meaning of company valuation. Below, you can find a link to the notes from his workshop about assessing a company prior to valuation. Assessing the Valuation of New … Continue reading Assessing the Valuation of New Ventures – MassChallengeCH, Lausanne, September 2017
Zurich, Bay Area & San Diego, CA – August 2017 – California Life Sciences Association (CLSA), the premier public policy advocacy and business leadership trade association representing California’s life sciences industry, and Venture Valuations Biotechgate, a global Life Sciences database today announced their collaboration to create an in-depth member directory for CLSA as well as a … Continue reading Venture Valuations Biotechgate Collaborates with California Life Sciences Association (CLSA) to Connect California’s Life Sciences Sector
The antibiotics market is expected to reach USD 57.0 billion by 2024. Rising prevalence of infectious diseases is contributing to the market growth, especially in developing regions such as Asia-Pacific. However, raising capital for companies active in this field has been difficult for the past few years. Thus, Venture Valuation has collected some important facts, … Continue reading Whitepaper: Focus on the Antibiotics Market
Last month, CEO of Venture Valuation, Dr Patrik Frei, delivered a live webinar titled ‘Valuation of Life Sciences Start-up’ to healthcare alumni of Harvard Business School You can watch the webinar here. Due to a large number of questions from participants, not all of them could be answered during the event. In this post, we … Continue reading Valuation of Life Sciences Start-up – Questions and Answers
On 7th of June 2017, CEO of Venture Valuation, Dr Patrik Frei, delivered a live webinar titled ‘Valuation of Life Sciences Start-up’ to healthcare alumni of Harvard Business School. The online event was a part of Healthcare Roundtable, a series of interactive presentations by industry leaders organised by HBS Healthcare Alumni Association. Dr. Frei talked about the significance … Continue reading Dr. Patrik Frei Delivers a Webinar to Harvard Business School Alumni
By leveraging expertise it has built up over decades in the HERV medical research and development, GeNeuro is engaging in unprecedented therapeutic development targeting HERVs. Venture Valuation (VV) interviewed Jesús Martin-Garcia, co-founder and CEO Read the interview.
Dr. Patrik Frei, Venture Valuation CEO and a worldwide known expert in life sciences company and product valuation, delivered a workshop on the topic during he Redefining Early Stage Investments Conference in San Diego. The notes from the workshop are available to download here.
